Table 3 Univariate and multivariate analyses of characteristics for completion of recruitment in clinical trials related to hip fractures

Outcome measures including mortality

 Yes

45.00% (36/80)

1.01 (0.62–1.63)

0.98

0.97 (0.56–1.68)

0.91

 No

44.87% (175/390)

Gender

 Male

75.00% (3/4)

0.99 (0.40–2.45)

0.98

1.48 (0.51–4.32)

0.47

 Female

53.33% (8/15)

 Both

44.35% (200/451)

Age including children

 Yes

57.50% (23/40)

1.74 (0.90–3.35)

0.10

2.27 (1.11–4.68)

0.03

 No

43.72% (188/430)

Age including older adults

 Yes

45.34% (209/461)

2.90 (0.60–14.12)

0.19

3.45 (0.62–19.26)

0.16

 No

22.22% (2/9)

Phases

 Not applicable

40.63% (128/315)

1.11 (0.99–1.24)

0.07

1.10 (0.94–1.28)

0.22

 Phase 1

50.00% (2/4)

 Phase 2

70.37% (19/27)

 Phase 3

61.22% (30/49)

 Phase 4

42.67% (32/75)

Enrollment

  ≤ 50

43.55% (54/124)

1.02 (0.88–1.17)

0.82

0.98 (0.82–1.15)

0.76

  > 50 and ≤ 100

42.86% (54/126)

  > 100 and ≤ 200

47.17% (50/106)

  > 200 and ≤ 400

54.41% (37/68)

  > 400

34.78% (16/46)

Funded by the NIH

 Yes

83.33% (15/18)

6.53 (1.86–22.87)

 < 0.01

8.71 (2.13–35.61)

 < 0.01

 No

43.36% (196/452)

Funded by industry

 Yes

50.00% (36/72)

1.27 (0.77–2.11)

0.34

1.61 (0.92–2.84)

0.10

 No

43.97% (175/398)

Allocation

 Not applicable

32.69% (17/52)

1.25 (0.94–1.66)

0.13

1.28 (0.80–2.05)

0.31

 Non-randomized

50.00% (18/36)

 Randomized

46.07% (176/382)

Intervention model

 Single

42.31% (33/78)

1.09 (0.89–1.35)

0.39

1.07 (0.78–1.49)

0.67

 Sequential

0.00% (0/3)

 Parallel

45.18% (164/363)

 Factorial

66.67% (6/9)

 Crossover

47.06% (8/17)

Masking

 None

44.09% (82/186)

1.01 (0.88–1.17)

0.86

0.86 (0.71–1.03)

0.10

 Single

45.60% (57/125)

 Double

45.78% (38/83)

 Triple

42.86% (12/28)

 Quadruple

45.83% (22/48)

 Primary purpose

Diagnostic

 Yes

25.00% (4/16)

0.40 (0.13–1.25)

0.12

0.72 (0.16–3.23)

0.67

 No

45.59% (207/454)

Health service research

 Yes

46.15% (6/13)

1.05 (0.35–3.18)

0.93

1.17 (0.27–5.07)

0.83

 No

44.86% (205/457)

Prevention

 Yes

40.54% (30/74)

0.81 (0.49–1.34)

0.41

0.80 (0.27–2.38)

0.69

 No

45.71% (181/396)

Supportive care

 Yes

44.44% (12/27)

0.98 (0.45–2.14)

0.96

0.90 (0.26–3.13)

0.87

 No

44.92% (199/443)

Treatment

 Yes

47.19% (151/320)

1.34 (0.90–1.99)

0.14

1.22 (0.46–3.27)

0.69

 No

40.00% (60/150)

Interventions

 Behavioral

  Yes

61.76% (21/34)

2.09 (1.02–4.28)

0.04

1.56 (0.67–3.64)

0.31

  No

43.58% (190/436)

 Drug/biological agent

  Yes

50.00% (71/142)

1.34 (0.91–1.99)

0.14

1.11 (0.60–2.05)

0.75

  No

42.68% (140/328)

 Device

  Yes

38.26% (44/115)

0.70 (0.45–1.07)

0.10

0.65 (0.38–1.13)

0.13

  No

47.04% (167/355)

 Procedure

  Yes

40.91% (54/132)

0.80 (0.53–1.20)

0.28

0.86 (0.52–1.40)

0.54

  No

46.45% (157/338)

 Location in China

  Yes

27.27% (12/44)

0.43 (0.22–0.85)

0.02

0.51 (0.23–1.15)

0.10

  No

46.71% (199/426)

 Location in the United States

  Yes

49.00% (49/100)

1.23 (0.79–1.92)

0.35

0.82 (0.43–1.54)

0.53

  No

43.78% (162/370)

 Location in Europe

  Yes

47.45% (93/196)

1.19 (0.83–1.73)

0.35

1.09 (0.66–1.82)

0.73

  No

43.07% (118/274)

 Location in Canada

  Yes

45.16% (14/31)

1.01 (0.49–2.10)

0.98

0.97 (0.41–2.28)

0.94

  No

44.87% (197/439)